OBJECTIVE: Induction of CYP3A by St. John's wort (SJW) products with high hyperforin content is well described. Since CYP3A induction is mediated by hyperforin in a concentration-dependent manner, and SJW preparations differ significantly in hyperforin content, the aim of the study was to evaluate the effect of an SJW powder with low hyperforin content on CYP3A function. METHODS: Twenty healthy male volunteers received an SJW powder with low hyperforin content for 2 weeks. Midazolam plasma concentration time profiles were characterized after a single oral dose of 7.5 mg midazolam on the day before and on the 14th day of SJW medication. RESULTS: Midazolam AUC(0-infinity) slightly decreased from 124.0 +/- 62.5 ng/ml.h at baseline to 105.6 +/- 53.2 ng/ml.h after SJW (P < 0.05), representing a mean 11.3% decrease (95% CI: -22.8 to 0.21). No significant change in midazolam C(max), t(1/2) and t(max) was observed. For all pharmacokinetic parameters, the 90% CI for the geometric mean ratio of treatment over baseline were within the no-effect boundaries of 0.70-1.43. CONCLUSION: Administration of an SJW product with low hyperforin content resulted in a mild induction of CYP3A not considered clinically relevant.
OBJECTIVE: Induction of CYP3A by St. John's wort (SJW) products with high hyperforin content is well described. Since CYP3A induction is mediated by hyperforin in a concentration-dependent manner, and SJW preparations differ significantly in hyperforin content, the aim of the study was to evaluate the effect of an SJW powder with low hyperforin content on CYP3A function. METHODS: Twenty healthy male volunteers received an SJW powder with low hyperforin content for 2 weeks. Midazolam plasma concentration time profiles were characterized after a single oral dose of 7.5 mg midazolam on the day before and on the 14th day of SJW medication. RESULTS:Midazolam AUC(0-infinity) slightly decreased from 124.0 +/- 62.5 ng/ml.h at baseline to 105.6 +/- 53.2 ng/ml.h after SJW (P < 0.05), representing a mean 11.3% decrease (95% CI: -22.8 to 0.21). No significant change in midazolam C(max), t(1/2) and t(max) was observed. For all pharmacokinetic parameters, the 90% CI for the geometric mean ratio of treatment over baseline were within the no-effect boundaries of 0.70-1.43. CONCLUSION: Administration of an SJW product with low hyperforin content resulted in a mild induction of CYP3A not considered clinically relevant.
Authors: M Wurglics; K Westerhoff; A Kaunzinger; A Wilke; A Baumeister; J Dressman; M Schubert-Zsilavecz Journal: J Am Pharm Assoc (Wash) Date: 2001 Jul-Aug
Authors: L B Moore; B Goodwin; S A Jones; G B Wisely; C J Serabjit-Singh; T M Willson; J L Collins; S A Kliewer Journal: Proc Natl Acad Sci U S A Date: 2000-06-20 Impact factor: 11.205
Authors: Ingrid Mai; Steffen Bauer; Elke S Perloff; Andreas Johne; Bernhard Uehleke; Bruno Frank; Klemens Budde; Ivar Roots Journal: Clin Pharmacol Ther Date: 2004-10 Impact factor: 6.875
Authors: Nielka P van Erp; Sharyn D Baker; Anthe S Zandvliet; Bart A Ploeger; Margaret den Hollander; Zhaoyuan Chen; Jan den Hartigh; Jacqueline M C König-Quartel; Henk-Jan Guchelaar; Hans Gelderblom Journal: Cancer Chemother Pharmacol Date: 2010-05-29 Impact factor: 3.333
Authors: Catherine Zahner; Esther Kruttschnitt; Julia Uricher; Michael Lissy; Martin Hirsch; Simon Nicolussi; Stephan Krähenbühl; Jürgen Drewe Journal: Clin Pharmacol Ther Date: 2019-03-23 Impact factor: 6.875
Authors: Irina-Iuliana Costache; Anca Miron; Monica Hăncianu; Viviana Aursulesei; Alexandru Dan Costache; Ana Clara Aprotosoaie Journal: Cardiovasc Ther Date: 2019-09-02 Impact factor: 3.023